ERIS LIFESCIENCES LTD Q1 FY27 Results Analysis: PAT Surges 20.7%, Margin Compresses 2 ppt
ERIS Lifesciences Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 873.25 Cr (+12.97% YoY) and PAT growth of +20.68% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 29, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 873.25 Cr (+12.97% YoY) |
| PAT (Q1) | Rs. 142.39 Cr (+20.68% YoY) |
| EBITDA margin | 33.88% (-200 bps YoY) |
| EPS (Q1) | Rs. 10.28 (+18.71% YoY) |
| Market cap | Rs. 19,818.35 Cr |
| CMP | Rs. 1,426.50 |
Quarter Snapshot
Eris delivered strong revenue growth of 13% YoY and PAT growth of 20.7%, but EBITDA margin compressed 2 ppt due to a material cost spike from product mix shift. Deleveraging continued with debt-equity improving to 0.64x, but the margin miss against the full-year guidance of 36% is a concern, though management had guided H1 weakness. The capex cycle for new facilities remains heavy.
Key Investment Insights
Key Positives
- Revenue grew 13.0% YoY to Rs.873.25 Cr, the strongest quarterly print in several quarters.
- PAT attributable to owners grew 20.7% YoY to Rs.142.39 Cr, outpacing EBITDA growth.
- Debt-equity ratio improved to 0.64 from 0.74 a year ago, confirming deleveraging.
- Interest service coverage ratio improved to 4.86× from 4.29×.
- Net worth grew 16% YoY to Rs.3,944 Cr.
Risk Factors
- EBITDA margin compressed 2.0 ppt YoY to 33.88%, driven by a 3.5 ppt increase in material cost as a share of revenue.
- Total material cost rose 29.6% YoY against revenue growth of 13.0%, indicating product mix shift to lower-margin products.
- Current ratio weakened to 0.60 from 0.93, reflecting working capital build-up.
- The 33.88% EBITDA margin is below the full-year guidance of 36%, though management guided H1 lower than H2.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.